J S Powell

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study
    Jerry Powell
    Division of Hematology Oncology, School of Medicine, University of California at Davis, Davis, California, USA
    Thromb Haemost 108:913-22. 2012
  2. pmc Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Jerry S Powell
    University of California, Davis, Sacramento, CA, USA
    Blood 119:3031-7. 2012
  3. ncbi request reprint Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A
    J S Powell
    University of California Davis Hemophilia Treatment Center, Sacramento, CA 95817, USA
    Haemophilia 6:140-9. 2000
  4. ncbi request reprint Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion
    Jerry S Powell
    Division of Hematology and Oncology, Suite 3016, UC Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817
    Blood 102:2038-45. 2003
  5. ncbi request reprint Liposomal approach towards the development of a longer-acting factor VIII
    J S Powell
    UC Davis Hemophilia Treatment Center, University of California, Davis Medical Center, Sacramento, CA, USA
    Haemophilia 13:23-8. 2007
  6. ncbi request reprint Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
    J S Powell
    Division of Hematology and Oncology, University of California at Davis, Sacramento, CA, USA
    J Thromb Haemost 6:277-83. 2008

Detail Information

Publications6

  1. doi request reprint Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study
    Jerry Powell
    Division of Hematology Oncology, School of Medicine, University of California at Davis, Davis, California, USA
    Thromb Haemost 108:913-22. 2012
    ..There were no safety concerns identified. The investigational treatment arm was prematurely discontinued due to failure to achieve the primary endpoint...
  2. pmc Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Jerry S Powell
    University of California, Davis, Sacramento, CA, USA
    Blood 119:3031-7. 2012
    ..Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377...
  3. ncbi request reprint Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A
    J S Powell
    University of California Davis Hemophilia Treatment Center, Sacramento, CA 95817, USA
    Haemophilia 6:140-9. 2000
    ..Furthermore, the heat-treated preparation is not associated with the development of inhibitors in previously treated patients...
  4. ncbi request reprint Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion
    Jerry S Powell
    Division of Hematology and Oncology, Suite 3016, UC Davis Cancer Center, University of California at Davis, 4501 X St, Sacramento, CA 95817
    Blood 102:2038-45. 2003
    ....
  5. ncbi request reprint Liposomal approach towards the development of a longer-acting factor VIII
    J S Powell
    UC Davis Hemophilia Treatment Center, University of California, Davis Medical Center, Sacramento, CA, USA
    Haemophilia 13:23-8. 2007
    ..Results from preclinical models and early clinical trials have shown that BAY 79-4,980 prolongs the time to the next bleed. Further clinical evaluation of the efficacy and long-term safety of BAY 79-4,980 are planned...
  6. ncbi request reprint Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
    J S Powell
    Division of Hematology and Oncology, University of California at Davis, Sacramento, CA, USA
    J Thromb Haemost 6:277-83. 2008
    ..BAY 79-4980 is a sucrose-formulated recombinant factor VIII (rFVIII-FS) combined with pegylated liposomes to prolong activity...